While a failed ebola drug helped treat hospitalized Covid-19 patients, the common cold virus could become key in treating advanced unresectable cancers.
San Diego-based Sorrento Therapeutics rejected a non-binding acquisition proposal from a private equity firm, saying that the offer “significantly undervalues Sorrento and is not in the best interest of the company’s stockholders.”
PsiOxus Therapeutics Ltd. agreed to grant Bristol-Myers Squibb Co. exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors.
